BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

505 related articles for article (PubMed ID: 17431033)

  • 21. Stereoselectivity in the oxidation of bufuralol, a chiral substrate, by human cytochrome P450s.
    Narimatsu S; Takemi C; Kuramoto S; Tsuzuki D; Hichiya H; Tamagake K; Yamamoto S
    Chirality; 2003 May; 15(4):333-9. PubMed ID: 12666241
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacogenetic explanation for excessive beta-blockade following timolol eye drops. Potential for oral-ophthalmic drug interaction.
    Edeki TI; He H; Wood AJ
    JAMA; 1995 Nov 22-29; 274(20):1611-3. PubMed ID: 7474246
    [TBL] [Abstract][Full Text] [Related]  

  • 23. O-Dealkylation of fluoxetine in relation to CYP2C19 gene dose and involvement of CYP3A4 in human liver microsomes.
    Liu ZQ; Zhu B; Tan YF; Tan ZR; Wang LS; Huang SL; Shu Y; Zhou HH
    J Pharmacol Exp Ther; 2002 Jan; 300(1):105-11. PubMed ID: 11752104
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro modulatory effects on three major human cytochrome P450 enzymes by multiple active constituents and extracts of Centella asiatica.
    Pan Y; Abd-Rashid BA; Ismail Z; Ismail R; Mak JW; Pook PC; Er HM; Ong CE
    J Ethnopharmacol; 2010 Jul; 130(2):275-83. PubMed ID: 20457244
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Optimizing higher throughput methods to assess drug-drug interactions for CYP1A2, CYP2C9, CYP2C19, CYP2D6, rCYP2D6, and CYP3A4 in vitro using a single point IC(50).
    Gao F; Johnson DL; Ekins S; Janiszewski J; Kelly KG; Meyer RD; West M
    J Biomol Screen; 2002 Aug; 7(4):373-82. PubMed ID: 12230892
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro metabolism of chloroquine: identification of CYP2C8, CYP3A4, and CYP2D6 as the main isoforms catalyzing N-desethylchloroquine formation.
    Projean D; Baune B; Farinotti R; Flinois JP; Beaune P; Taburet AM; Ducharme J
    Drug Metab Dispos; 2003 Jun; 31(6):748-54. PubMed ID: 12756207
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of metabolic pathways involved in the biotransformation of tolperisone by human microsomal enzymes.
    Dalmadi B; Leibinger J; Szeberényi S; Borbás T; Farkas S; Szombathelyi Z; Tihanyi K
    Drug Metab Dispos; 2003 May; 31(5):631-6. PubMed ID: 12695352
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Metabolism-mediated drug interactions associated with ritonavir-boosted tipranavir in mice.
    Li F; Wang L; Guo GL; Ma X
    Drug Metab Dispos; 2010 May; 38(5):871-8. PubMed ID: 20103582
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The polymorphic cytochrome P-4502D6 is involved in the metabolism of both 5-hydroxytryptamine antagonists, tropisetron and ondansetron.
    Fischer V; Vickers AE; Heitz F; Mahadevan S; Baldeck JP; Minery P; Tynes R
    Drug Metab Dispos; 1994; 22(2):269-74. PubMed ID: 8013282
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of human hepatic cytochrome P450 enzymes involved in the metabolism of 8-prenylnaringenin and isoxanthohumol from hops (Humulus lupulus L.).
    Guo J; Nikolic D; Chadwick LR; Pauli GF; van Breemen RB
    Drug Metab Dispos; 2006 Jul; 34(7):1152-9. PubMed ID: 16611861
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cytochrome P450 metabolic dealkylation of nine N-nitrosodialkylamines by human liver microsomes.
    Bellec G; Dréano Y; Lozach P; Ménez JF; Berthou F
    Carcinogenesis; 1996 Sep; 17(9):2029-34. PubMed ID: 8824531
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro metabolism of the analgesic bicifadine in the mouse, rat, monkey, and human.
    Erickson DA; Hollfelder S; Tenge J; Gohdes M; Burkhardt JJ; Krieter PA
    Drug Metab Dispos; 2007 Dec; 35(12):2232-41. PubMed ID: 17881661
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enantiomer/enantiomer interactions between the S- and R- isomers of omeprazole in human cytochrome P450 enzymes: major role of CYP2C19 and CYP3A4.
    Li XQ; Weidolf L; Simonsson R; Andersson TB
    J Pharmacol Exp Ther; 2005 Nov; 315(2):777-87. PubMed ID: 16093273
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biotransformation of 6-methoxy-3-(3',4',5'-trimethoxy-benzoyl)-1H-indole (BPR0L075), a novel antimicrotubule agent, by mouse, rat, dog, and human liver microsomes.
    Yao HT; Wu YS; Chang YW; Hsieh HP; Chen WC; Lan SJ; Chen CT; Chao YS; Chang L; Sun HY; Yeh TK
    Drug Metab Dispos; 2007 Jul; 35(7):1042-9. PubMed ID: 17403915
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 2,5-Dimethoxyamphetamine-derived designer drugs: studies on the identification of cytochrome P450 (CYP) isoenzymes involved in formation of their main metabolites and on their capability to inhibit CYP2D6.
    Ewald AH; Maurer HH
    Toxicol Lett; 2008 Dec; 183(1-3):52-7. PubMed ID: 18938231
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Metabolism of Benzalkonium Chlorides by Human Hepatic Cytochromes P450.
    Seguin RP; Herron JM; Lopez VA; Dempsey JL; Xu L
    Chem Res Toxicol; 2019 Dec; 32(12):2466-2478. PubMed ID: 31730751
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of dolasetron. Comparison with other indole-containing 5-HT3 antagonists.
    Sanwald P; David M; Dow J
    Drug Metab Dispos; 1996 May; 24(5):602-9. PubMed ID: 8723743
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nortriptyline E-10-hydroxylation in vitro is mediated by human CYP2D6 (high affinity) and CYP3A4 (low affinity): implications for interactions with enzyme-inducing drugs.
    Venkatakrishnan K; von Moltke LL; Greenblatt DJ
    J Clin Pharmacol; 1999 Jun; 39(6):567-77. PubMed ID: 10354960
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Validation of (-)-N-3-benzyl-phenobarbital as a selective inhibitor of CYP2C19 in human liver microsomes.
    Cai X; Wang RW; Edom RW; Evans DC; Shou M; Rodrigues AD; Liu W; Dean DC; Baillie TA
    Drug Metab Dispos; 2004 Jun; 32(6):584-6. PubMed ID: 15155548
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Conversion of the HIV protease inhibitor nelfinavir to a bioactive metabolite by human liver CYP2C19.
    Hirani VN; Raucy JL; Lasker JM
    Drug Metab Dispos; 2004 Dec; 32(12):1462-7. PubMed ID: 15448116
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.